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Abstract
Introduction: Yaws, caused by Treponema pallidum ssp. pertenue, is
endemic in parts of West Africa, Southeast Asia and the Paciﬁc. The WHO
has launched a campaign based on mass treatment with azithromycin, to
eradicate yaws by 2020.
Sources of data: We reviewed published data, surveillance data and data
presented at yaws eradication meetings.
Areas of agreement: Azithromycin is now the preferred agent for treating
yaws. Point-of-care tests have demonstrated their value in yaws.
Areas of controversy: There is limited data from 76 countries, which previ-
ously reported yaws. Different doses of azithromycin are used in community
mass treatment for yaws and trachoma.
Growing points: Yaws eradication appears an achievable goal. The pro-
gramme will require considerable support from partners across health and
development sectors.
Areas timely for developing research: Studies to complete baseline
mapping, integrate diagnostic tests into surveillance and assess the impact
of community mass treatment with azithromycin are ongoing.
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Introduction
Yaws is an infectious disease caused by Treponema
pallidum ssp. pertenue and is one of the four trepo-
nemal diseases affecting humans.1,2 Unlike syphilis,
which is caused by the almost identical T. pallidum
pallidum, it is not sexually transmitted, but is
thought to be spread by skin to skin contact in warm
humid environments, and mother to child transmis-
sion is not seen. As with other treponemal infections,
yaws causes primary, secondary and tertiary lesions,
which predominantly affect the skin, bones and
cartilage. Yaws was the ﬁrst disease to be targeted
for eradication by the World Health Organization
(WHO), and mass screening and treatment pro-
grammes led by WHO reduced the global prevalence
by >95% between 1950 and 1964, but it has re-
emerged as an important public health problem in
West Africa, Southeast Asia and the Paciﬁc in recent
years.3 The recent demonstration that a single oral
dose of azithromycin is as effective as injectable
penicillin in the treatment of yaws4 has prompted
renewed interest in the possibility of yaws eradica-
tion, but barriers such as funding and access to
azithromycin have to be overcome before this goal
can be realized.
Epidemiology
Yaws is found in warm and humid environments5
and affects mostly children between 2 and 15 years
old, who are considered as the reservoir for infec-
tions. The disease is spread by direct skin-to-skin,
non-sexual, contact often after a cut or abrasion in
the lower legs.6 There have been suggestions that
ﬂies may act as a vector for yaws,6 but there is no
deﬁnitive proof that this occurs. Treponemal infec-
tions closely related to yaws and syphilis have been
identiﬁed in primates, but there is no evidence to
suggest that zoonotic transmission between humans
and non-human primates occurs.7 Children born to
mothers affected with yaws are generally unaffected,
and most evidence seems to indicate that the disease
is not acquired congenitally.
The early lesions of yaws are most infectious. It is
estimated that patients are infectious for up to 12–18
months following primary infection,6 but relapsing
disease can extend this period. The destructive
lesions of late yaws are not infectious. In studies in
both Papua New Guinea and the Solomon Islands,
endemicity at the village level has been identiﬁed as
the major risk factor for infection and re-infection
following treatment.8,9 The disease primarily affects
rural communities with low standards of hygiene,
with incidence declining as social and economic
status rise.
In the mid-20th century, yaws was reported to
affect ∼50 million individuals and to be endemic in
at least 90 countries10 in South America, the Carib-
bean, Africa, Asia and the Paciﬁc. The WHO
launched a major eradication effort in the 1950s
based on mass screening and treatment with inject-
able penicillin. The campaign examined some 300
million individuals of whom 50 million were treated.
Although yaws was not eradicated, by the end of the
major campaign in 1964, the burden of yaws had
been signiﬁcantly reduced to ∼2.5 million cases.3
Following this initial success of the WHO cam-
paign, yaws dropped down the public health agenda
internationally and domestically in many countries.
In the 1970s and 1980s, there was a resurgence
of cases in some countries in West and Central
Africa.11,12 This led to a renewal of control efforts,
which again reduced the burden of the disease but
did not eradicate it.
Over the past 20 years, there has been a further
resurgence of yaws in previously endemic countries,
and the disease is now thought to be endemic in at
least 12 countries in West Africa, Southeast Asia and
the Paciﬁc. There are a further 76 countries that
previously reported yaws, throughout Africa, the
Americas, Asia and the Paciﬁc, for which adequate
up-to-date surveillance data are not currently avail-
able (Fig. 1).10 Most yaws cases are concentrated in
just three countries: Ghana, Papua New Guinea and
the Solomon Islands have each reported >15 000
cases annually within the last 3 years. In another
eight countries, transmission occurs in focal com-
munities. Despite being deprioritized in inter-
national health fora, both India and Ecuador have
reported eliminating yaws in recent years with pro-
longed campaigns based on case identiﬁcation,
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contact tracing and treatment with injectable penicil-
lin,13 demonstrating that sustained efforts can be
successful.
Bacteriology
Treponema pallidum is a spirochaete that cannot be
cultured in vitro.6 They divide slowly (every 30 h),
have a characteristic corkscrew-like motility and can
move through gel-like environments such as connect-
ive tissue. They are rapidly killed by drying, oxygen
exposure or heating, and they cannot survive outside
the mammalian host. The four pathogenic trepo-
nemes are morphologically and serologically indis-
tinguishable, and share at least 99% DNA sequence
homology.14 Whole-genome sequencing has demon-
strated that the genome of T. p ssp. pertenue differs
by only 0.2% from that of T. p ssp. pallidum,14 the
causative organism of venereal syphilis. The phylo-
genetic relationship between different subspecies of
treponemes is not clear, as very few isolates of the
non-venereal subspecies are available.15
Clinical features
As with other treponemal diseases, the clinical features
of yaws may be conveniently divided into primary, sec-
ondary and tertiary disease.2,6,16 Although this classiﬁ-
cation is clinically useful, it should be remembered that
patients may present with a mixture of clinical signs.
Primary yaws
The initial lesion of primary yaws is a papule ap-
pearing at the site of inoculation after ∼21 days
(range 9–90 days).6 This ‘Mother Yaw’ may evolve
either into an exudative papilloma, 2–5 cm in size,
or degenerate to form a single, crusted, non-tender
ulcer (Fig. 2). The lower limbs are the commonest
site for primary yaws lesions, but other parts of the
body may all be affected. Unlike venereal syphilis,
genital lesions are extremely uncommon. In untreated
individuals, primary lesions may heal spontaneously
over a period of 3–6 months, leaving a pigmented
scar.17 Primary lesions may still be present in patients
who present with secondary yaws.
Fig. 1 Worldwide distribution of yaws. Data taken from the World Health Organization. Global Health Observatory Data
Repository. http://apps.who.int/gho/data/node.main.NTDYAWSEND?lang=en (2 October 2014, date last accessed).
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Secondary yaws
After a period of 1–2 months (sometimes up to 24
months), haematogenous and lymphatic spread of tre-
ponemes may result in progression to secondary yaws,
which predominantly affects the skin and bones,18,19
often with general malaise and lymphadenopathy.
As with venereal syphilis, a wide range of skin
manifestations has been described in secondary yaws
(Fig. 3). Patients may develop disseminated papillo-
matous or ulcerative lesions, scaly macular lesions or
hyperkeratotic lesions on the palms and soles.6,19
Hyperkeratotic lesions can crack and become sec-
ondarily infected, resulting in severe pain and a crab-
like gait (crab-yaws).20 Mucous membrane involve-
ment is uncommon in secondary yaws.21
Alongside the skin, involvement of the bones is
one of the cardinal features of secondary yaws. The
most common manifestation is osteoperiostitis,
involving the ﬁngers (resulting in dactylitis) or long
bones (forearm, ﬁbula and tibia) which results in
bony swelling and pain (Fig. 4).18 In most patients,
multiple bones can be affected. In a study from
Papua New Guinea,19 75% of children with second-
ary yaws had joint pain. Following treatment of
primary or secondary yaws, skin lesions usually
resolve within 2–4 weeks and bone pain may begin
to resolve in as little as 48 h.1,2
As in all treponemal infections, untreated patients
may develop latent infection, with positive serology
but no clinical signs. Latent cases can relapse,
usually in the ﬁrst 5 years (rarely up to 10 years)
after infection.6 Relapsing lesions tend to occur
around the axillae, anus and mouth.
Tertiary yaws
The destructive lesions of tertiary yaws were previ-
ously reported to occur in up to 10% of untreated
patients but are now rarely seen. As in other stages of
the disease, the skin is most commonly affected.
Nodular lesions may occur near joints and ulcerate,
causing tissue necrosis.5 Destructive lesions of the
face were one of the most marked manifestations of
late-stage yaws. Gangosa, a destructive osteitis of the
palate and nasopharynx, results in mutilating facial
Fig. 2 Lesions of primary yaws. A, typical ulcer of primary yaws. B, papilloma of primary yaws (Images
reproduced with permission of M.M. and O.M.).
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ulceration. Goundou, which was rarely reported
even when yaws was hyperendemic, is characterized
by exostoses of the maxillary bones.2
Unlike syphilis, yaws is not thought to cause car-
diovascular or neurological disease.2 Post-mortem
studies in a yaws-endemic community in Ghana
found that aortitis, histologically similar to that
found in tertiary syphilis, was the most common
cardiovascular abnormality, but deﬁnitive evidence
that this was due to yaws is lacking.
Attenuated disease
The manifestations of yaws appear to be less ﬂorid
than previously described.22 In particular, tertiary
manifestations are now rarely seen. There is no
agreed deﬁnition of attenuated yaws, nor a clear
explanation for why the clinical features of the
disease may have changed, although improvements
in living standards, use of treponemocidal antibiotics
for other infections and mutations in T. p ssp. perte-
nue have all been proposed.22
Diagnosis
Treponema pallidum is not viable ex vivo, which has
limited the value of direct diagnostic methods. While
dark ﬁeld microscopy allows direct visualization of
spirochaetes,6 the skills and equipment required are
not available in most locations even in relatively
high-income settings. Instead diagnosis has rested on
Fig. 3 Skin lesions of secondary yaws. A, Crusted maculopapular lesion of secondary yaws. B, Multiple
ulcers of secondary yaws (Images reproduced with permission of M.M. and O.M.).
Fig. 4 Bony lesions of secondary yaws. Dactylitis due to
secondary yaws (Images reproduced with permission of O.M.).
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combinations of serological assays and, more
recently, nucleic acid ampliﬁcation tests (NAATs).
As with venereal syphilis, serology has been the
mainstay of laboratory diagnosis.23 Serological
detection of yaws requires detection of two distinct
antibodies: one against a treponemal antigen and
one against a non-treponemal antigen. Treponema
pallidum particle agglutination (TPPA) and haem-
agglutination (TPHA) assays are used to detect
Treponema-speciﬁc antibodies. Once positive, these
tests usually remain positive for life. The venereal
disease research laboratory (VDRL) and rapid
plasma reagin (RPR) tests are non-treponemal tests,
which may give rise to biological false positives, but
more accurately reﬂect active disease and can be used
as a test of cure, since titres fall following successful
treatment.
A major challenge for clinicians and epidemiolo-
gists has been that the pathogenic treponemes are
serologically indistinguishable. Given the consider-
able epidemiological and clinical overlap between
the syndromes, this continues to represent a barrier
to accurate data on the incidence and prevalence of
yaws.
While serological assays do not require sophisti-
cated equipment, they do require access to labora-
tory facilities, which are rarely available to the
remote communities where yaws is endemic. Rapid
diagnostic tests (RDTs) have proved effective in the
diagnosis of syphilis,24 and a number of evaluations
of their performance in diagnosing yaws have
recently been undertaken. In Papua New Guinea, an
RDT (Chembio Diagnostic System, Inc., New York,
NY, USA) that detects both treponemal and non-
treponemal antibodies was shown to be valuable in
providing serological conﬁrmation of clinically sus-
pected cases.25 In the Solomon Islands, the same
RDT was shown to be of use for community surveil-
lance and mapping.26 These tests may help to
improve reporting practices for yaws worldwide.
Polymerase chain reaction (PCR) tests have been
commonly adopted for the diagnosis of venereal
syphilis, but distinguishing between subspecies of T.
pallidum currently relies on combined PCR and
sequencing27 and is only available at research labora-
tories. PCR has also emerged as a tool for diagnosing
other causes of skin lesions in yaws-endemic popula-
tions, including Haemophilus ducreyi.28,29 Wider
access to NAAT-based diagnostics, including pos-
sible point-of-care tests, will be required as part of
the WHO yaws eradication programme.
Diagnostic quandaries
The differential diagnosis of tropical ulcerative
lesions is broad30 and varies depending on the stage
and type of lesion. As examples, the primary lesions
of yaws may be mistaken for cutaneous leishmania-
sis, tropical ulcer caused by fusobacteria and
Treponema vincentii, or pyoderma. Of particular
importance is the emergence of H. ducreyi, the
causative organism of the sexually transmitted
disease chancroid, as a common cause of non-genital
skin lesions in a number of countries where yaws is
endemic. There are now reports of H. ducreyi as
a cause of non-genital skin lesions from Papua
New Guinea, the Solomon Islands, Ghana and
Vanuatu.28,29 Data from experimental models of
chancroid suggest that these lesions should be
responsive to azithromycin,31 and therefore, that
mass distribution of azithromycin for yaws (and pos-
sibly trachoma) could also be effective in treating
lesions resulting from infection withH. ducreyi.
Treatment
Long acting, injectable penicillin has been the
mainstay of treatment for yaws for over 50 years6
and was the cornerstone of all previous yaws control
and eradication programmes. Despite extensive use,
T. pallidum remains exquisitely sensitive to penicil-
lin, with no evidence that resistance has emerged.
There have been rare reports of treatment failure fol-
lowing treatment with penicillin, but the difﬁculty of
distinguishing treatment failure from reinfection
makes the signiﬁcance of these ﬁndings uncertain.32
The major drawback of injectable penicillin has been
the requirement for trained medical staff to adminis-
ter treatment, the risk of transmitting blood-borne
infections and the possible risk of anaphylaxis. The
recommended doses of benzathine penicillin for the
treatment of yaws (1.2 MU for adults, 0.6 MU for
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children) are lower than those used in venereal syph-
ilis,6 and in situations where the diagnosis is unclear,
clinicians are advised to treat for syphilis.16
Before 2012, no other agents had been evaluated
against yaws in randomized controlled trials, but
there are published observational data suggesting
prolonged courses of oral penicillin or tetracyclines
could be effective.33,34 Erythromycin has also been
recommended based on its efﬁcacy in the treatment
of venereal syphilis. These treatment options are of
less relevance since the emergence of azithromycin as
an effective treatment for yaws.
The macrolide antibiotic azithromycin was previ-
ously shown to be effective in treating venereal syph-
ilis.35 A landmark paper published in 2012 compared
a single oral dose of azithromycin (30 mg/kg) to
benzathine penicillin in the treatment of primary
and secondary yaws.4 Azithromycin was non-
inferior to penicillin, with clinical and serological
cure in 96% of individuals randomized to treatment
with azithromycin.
Azithromycin has a number of advantages as
an agent in the treatment of yaws. It is orally admi-
nistered and has a favourable safety proﬁle. It has
been widely and successfully used in mass drug
administration programmes for the control and elim-
ination of trachoma.36 One area of concern is the
possibility of resistance to azithromycin, which is
now widespread in sexually transmitted strains of
T. pallidum.37,38 Monitoring for the development of
resistance in T. p ssp. pertenue will be an extremely
important component of the WHO yaws eradication
strategy.
Eradication efforts
The emergence of azithromycin as an effective,
single-dose oral agent for the treatment of yaws has
led to renewed interest in the disease. In 2012, the
WHO outlined a new strategy (the Morges strategy)
for yaws eradication.39 This strategy is based on
community mass treatment with single-dose oral
azithromycin, with subsequent clinical case detection
to direct further rounds of mass or targeted treat-
ment with azithromycin. The WHO is aiming to
eradicate the disease by 2020.39
The previous WHO programmes in the 1950s to
1960s resulted in signiﬁcant reductions in the world-
wide burden of yaws3 but did not successfully eradi-
cate it. It is thought that a failure to adequately
identify and treat contacts and latent cases alongside
a lack of integration of yaws surveillance in to
national health programmes were responsible for
thisfailure.40
Both India and Ecuador have reported eliminat-
ing yaws since 2000, and their experiences are
informative for the current global eradication cam-
paign. Ecuador experienced a large drop in yaws
incidence and prevalence following the initial WHO
campaigns of the 1950s,13 but further control efforts
were complicated by the anecdotal nature of case
reporting. Ecuador instituted a more sustained sur-
veillance programme in the late 1980s, combining
continuous village-level monitoring for skin lesions
with formal surveys conducted every 5 years that
included clinical and serological screening. Indivi-
duals identiﬁed as having yaws (active or latent) were
treated with injectable benzathine penicillin. In
surveys conducted between 1988 and 1993, the
prevalence of yaws dropped by over 90%, and in a
follow-up survey conducted in 1998, no new cases
were been detected.13
In India, initial eradication efforts were launched
in the 1950s, but the disease rebounded in the 1970
and 1980’s. In 1996, the government launched a
yaws eradication programme.41 As in Ecuador, the
programme involved a combination of clinical
screening and treatment with intermittent serological
surveys. A notable aspect was the provision of ﬁnan-
cial incentives for individuals to report suspected
cases to the control programme.41 As in Ecuador,
the programme drove a sustained reduction in yaws
incidence from 3571 cases in 1996 to 0 cases in
2004.
Despite optimism surrounding mass distribution
of azithromycin, there remain major barriers to a
successful eradication programme. Notably, there
are limited accurate epidemiological data from many
countries where yaws is currently reported. Most
national surveillance systems report clinically sus-
pected cases only, without serological or PCR con-
ﬁrmation. Given the wide range of phenotypically
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similar skin lesions that may occur, it is likely that
these ﬁgures are inaccurate. Capacity building to
support improved surveillance is a central compo-
nent of the current eradication campaign. This is
compounded by the absence of recent data from
many countries where yaws was previously reported
to be endemic.10 Signiﬁcant investment in mapping
and epidemiology will be required to go along with
the eradication programme. Given the ambitious
timescales involved, innovative approaches combin-
ing mapping with other NTD or disease mapping
activities should be considered.
The eradication programme also lacks dedicated
funding and a drug donation programme. The cost
of eradication has been estimated to be in the region
of $112 million dollars, excluding drug costs, with a
cost of ∼$21 per DALY saved42 that compares
favourably to many other public health interven-
tions. As data from a larger number of previously
endemic countries become available, it is possible
that the total cost of the eradication programme may
be revised upwards substantially, although efﬁcien-
cies of scale may bring the cost per DALY down.
Yaws is known to be endemic in several countries
where trachoma is also found, including the Solomon
Islands and Vanuatu, and co-ordinated mapping
efforts have been undertaken or proposed in some of
these countries. As both diseases are controlled by
mass distribution of azithromycin, and there is
already a dedicated drug donation scheme for trach-
oma elimination, the possibility of integrating yaws
and trachoma control efforts warrants further study.
Particular attention will need to be paid to the efﬁ-
cacy of the lower dose of azithromycin (20 mg/kg)
used in trachoma control programmes for the treat-
ment of yaws.
Conclusions
Yaws remains a problem for poor, rural commu-
nities in many countries and places a signiﬁcant
burden on national health-care systems. As with the
other treponemal diseases, it has a multi-stage
disease course predominantly involving the skin and
bones. Yaws remains sensitive to penicillin, but
azithromycin has emerged as an effective treatment
that will be the cornerstone of the WHO-led eradica-
tion efforts, providing that it can be delivered to the
populations that need it.
The eradication of yaws will require considerable
support from partners across the health and develop-
ment sectors, and a number of challenges need to be
overcome for this effort to be successful. Accurate
epidemiological data are lacking from both currently
and formerly endemic countries, and a signiﬁcant
investment to improve this situation is urgently
needed. The development and validation of near-
patient and laboratory tests speciﬁc for treponemal
subspecies are urgently required, in view of the
increasing recognition that other bacteria can cause
phenotypically indistinguishable skin lesions. Inte-
gration of these tools, and monitoring for the emer-
gence of macrolide resistance, will be of critical
importance as the programme moves forward.
Despite these concerns, signiﬁcant progress has been
made in the last 5 years, raising hopes that yaws
eradication may ﬁnally become possible.
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